new oral glp 1 agonist In the phase 3 ACHIEVE-1 trial, published in June 2025, the small-molecule GLP-1 receptor orforglipron significantly reduced the glycated hemoglobin level over a period of 40 weeks in adults with Oral GLP-1: A Needle-Free Solution

As compounding pharmacists at Bayview Pharmacy, we are committed to providing you with the most accurate and up-to-date information about our formulations

While some Redditors have expressed curiosity about even more detailed testing (like full Certificates of Analysis for individual ingredients), the consensus is that TL's current testing protocols exceed industry standards

1992 Jan;26(1):22-5

GLP-1R activity also promotes the transactivation of epidermal growth factor receptor (EGFR), which then signals through phosphoinositide 3-kinase (PI3K) and insulin receptor substrate-2 (IRS-2), and subsequently activates extracellular-signal-regulated kinase 1 and 2 (ERK1/2) and nuclear translocation of PKC to mediate -cell proliferation and differentiation (114)